Newer antiarrhythmic drugs

Indian Heart Journal

Volumn 53, Issue 3, 2001, Pages 354-360

  Gupta, Anoop K ^b   Maheshwari, Alok ^b   Thakur, Ranjan K ^b   Lokhandwala, Yash Y ^a  

^a KEM HOSPITAL   (India)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; AZIMILIDE; DOFETILIDE; DRONEDARONE; IBUTILIDE; POTASSIUM CHANNEL; TEDISAMIL; TRECETILIDE; UNCLASSIFIED DRUG;

ANTIARRHYTHMIC ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ELECTROPHYSIOLOGY; HUMAN; REVIEW;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ATRIAL FIBRILLATION; ATRIAL FLUTTER; BICYCLO COMPOUNDS, HETEROCYCLIC; CYCLOPROPANES; DRUG APPROVAL; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; PHENETHYLAMINES; PIPERAZINES; SULFONAMIDES;

EID: 0034864573     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-1851
2. + channels in the cardiovascular system. J Cardiovasc Electrophysiol 1997; 8: 1431-1446
3. Hester JB, Gibson JK, Cimini MG, Emmert DE, Locker PK, Perricone SC, et al. N-[(omega-amino-1-hydroxyalkyl) phenyl]methanesulfonamide derivatives with class III antiarrhythmic activity. J Med Chem 1991; 34: 308-315
4. KR) in AT-1 cells: concentration-, time-, voltage-, and use-dependent effects. Circulation 1995; 91: 1799-1806
5. KR, and effects on myocardial refractoriness for class III antiarrhythmic agents. J Cardiovasc Pharmacol 1995; 25: 336-340
6. Buchanan LV, Kabell G, Turcotte UM, Brunden MN, Gibson JK. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide. J Cardiovasc Pharmacol 1992; 19: 256-263
7. Friedrichs GS, Chi L, Black SC, Manely PJ, Oh JY, Lucchesi BR. Antifibrillatory effects of ibutilide in the rabbit isolated heart: mediation via ATP-dependent potassium channels. J Pharmacol Exp Ther 1993; 266: 1348-1354
8. Wesley RC Jr, Farkhani F, Morgan D, Zimmermann D. Ibutilide: enhanced defibrillation via plateau sodium current activation. Am J Physiol 1993; 264: H1269-H1274.
9. Stambler BS, Beckman KJ, Kadish AH, Camm JA, Ellenbogen KA, Perry KT, et al. Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Am J Cardiol 1997; 80: 458-463
10. Ellenbogen KA, Stamber BS, Wood MA, Sager PT, Wesley RC, Meissner MC, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-dependent study. J Am Coll Cordiol 1996; 28: 130-136
11. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, Vanderlugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613-1621
12. Oral H, Souza JJ, Michaud GF, Knight BY, Goyal R, Strickberger SA, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340: 1849-1854
13. + current in rabbit ventricular myocytes. Cardiovasc Drugs Ther 1993; 7 (Suppl 3): 599-604
14. Kiehn J, Lacerda AE, Wible B, Brown AM. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 1996; 94: 2572-2579
15. Demolis JL, Funck-Brentano C, Ropers J, Ghabanfar M, Nichols DJ, Jallion P. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996; 94: 1592-1599
16. Sedgwick MI, Rasmussen HS, Cobbe SM. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68, 798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am J Cardiol 1992; 69: 513-517
17. Walker DK, Alabaster CT, Congrave GS, Hargreaves MB, Hyland R, Jones BC, et al. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos 1996; 24: 447-455
18. Kobayashi Y, Atarashi H, Ino T, Kuruma A, Nomura A, Saitoh H. Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias. J Cardiovasc Pharmacol 1997; 30: 367-373
19. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 1997; 29: 385-390
20. Echt DS, Lee JT, Murry KT, Vorperian V, Borganelli SM, Crawford DM, et al. A randomized double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophysiol 1995; 6: 687-699
21. Bashir Y, Thomsen PE, Kingma JH, Moller M, Wong G, Cobbe SM, et al. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68, 798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. Am J Cardiol 1995; 76: 1040-1044
22. Nademanee K, Bailey W, O'Neill G, Satler C, Friedrich T. Electrophysiologic and hemodynamic effects of dofetilide in patients with left ventricular function: a randomized, double-blind, placebo controlled study (Abstr). Pacing Clin Electrophysiol 1998; 21: 867
23. Ferguson J. Clinical trials. Clin Cardiol 1998; 21: 51-54
24. Dofetilide investigators. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigation of Arrhythmia and Mortality on Dofetilide. Clin Cardiol 1997; 20: 704-710
25. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341: 857-865
26. Waldo AL, Camm AJ, deRuyter H, Friedman PL, Mac Neil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-sotalol. Lancet 1996; 348: 6-12
27. Singh S, Berk M, Yellen IG, Zable RG, Abrahamson D, Satler CA. Efficacy and safety of oral dofetilide in maintaining normal sinus rhythm in patients with atrial fibrillation/flutter: a multicenter study (Abstr). Circulation 1997; 96 (Suppl 1): 383
28. Dalrymple H, Campbell T, Channer KS, Kingma JH, Greenbaum RA, Santini M, et al. Maintenance of sinus rhythm by dofetilide improves quality of life. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study (Abstr). Circulation 1998; 98 (Suppl 1): 13-14
29. Pederson O. The DIAMOND Study Group: dofetilide in the treatment of atrial fibrillation in patients with impaired left ventricular function: atrial fibrillation in the DIAMOND study (Abstr). Circulation 1998; 98 (Suppl 1): 632-633
30. Karam R, Marcello S, Brooks RR, Corey AE, Moore A. Azimilide dihydrochloride, a novel antiarrhythmic agent Am J Cardiol 1998; 81: 40D-46D
31. Pritchett ELC, Connelly S, Page R, Marcello SR, Schnell DJ, Wilknson WE. Survival in patients treated with azimilide for atrial fibrillation and other supraventricular arrhythmias (Abstr). Eur Heart J 1999; 20: 352
32. Connelly S, Page R, Marcello S, Schnell DJ, Wilkinson WE, Pritchett ELC. Dose response of azimilide for prevention of atrial fibrillation or flutter (Abstr). Eur Heart J 1999; 20: 351
33. Pritchett ELC, Page R, Connelly S, Schnell DJ, Marcello S, Wilkinson WE. Azimilide treatment in atrial fibrillation. Circulation 1999; 98 (Suppl 1): 633
34. Page R, Connelly S, Marcello S, Schnell DJ, Wilkinson WE, Pritchett ELC, et al. Dose response for azimilide treatment of paroxysmal supraventricular tachycardia (Abstr). Eur Heart J 1999; 20: 586
35. Camm AJ, Karam R, Pratt CM. The azimilide post-infarct survival evaluation (ALIVE) trial. Am J Cardiol 1998; 81: 35D-39D
36. Manning AS, Bruyninckx C, Ramboux J, Chatelain P. SR 33589, a new amiodarone-like agent: effect on ischemia and reperfusion induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol 1995; 26: 453-461
37. Chatelain P, Meysmans L, Matteazzi JR, Beaufort P, Clinet M. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol 1995; 116: 1949-1956
38. Hodeige D, Heyndrickx JP, Chatelain P, Manning A. SR 33589, a new amiodarone like antiarrhythmic agent: anti-adrenoceptor activity in anesthetized and conscious dogs. Eur J Pharmacol 1995; 279: 25-32
39. Manning A, Thisse V, Hodeige D, Richard J, Heyndricksx JP, Chatelain P. SR 33589, a new amiodarone like antiarrhythmic agent: electrophysiological effects in anesthetized dogs. J Cardiovasc Pharmacol 1995; 25: 252-261
40. Verduyn SC, Vos MA, Leunissen HD, van Opstal JM, Wellens HJ. Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias. J Cardiovasc Pharmacol 1999; 33: 212-222
41. Sun W, Sharma JS, Singh BN. Electrophysiogical effects of dronedarone (SR 33589), a non-iodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 1999; 100: 2276-2281
42. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997; 35: 13-29
43. Friedrichs GS, Abreu JN, Driscoll EMJ, Borlak J, Lucchesi BR. Antifibrillatory efficacy of long-term tedisamil administration in a post-infarcted canine model of ischemic ventricular fibrillation. J Cardiovasc Pharmacol 1998; 31: 56-66
44. Chi L, Park JL, Friedrichs GS, Banglawala YA, Perez MA, Tanheheo EJ, et al. Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br J Pharmacol 1996; 117: 1261-1269
45. Wettwer E, Himmel HM, Amos GJ, Li Q, Metzger F, Ravens U. Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Br J Pharmacol 1998; 125: 659-666
46. Bargheer K, Bode F, Klein HU, Trappe HJ, Franz MR, Lichtlen PR. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. Eur Heart J 1994; 15: 1409-1414
47. + channel current. Circ Res 1993; 73: 210-216
48. Yue L, Feng J, Li GR, Nattel S. Characterization of an ultra-rapid delayed rectifier potassium channel involved in canine atrial repolarization. J Physiol 1996; 496: 647-662
49. Feng J, Xu D, Wang Z, Nattel S. Ultra-rapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. Am J Physiol 1998; 275: H1717-H1725